Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Cellulose based nanofiber-assisted stabilization of cationic ethosomes for skin penetration of bleomycin sulphate in the treatment of skin cancer.

International journal of biological macromolecules·2025
Same author

Behavioral neuroscience in zebrafish: unravelling the complexity of brain-behavior relationships.

Naunyn-Schmiedeberg's archives of pharmacology·2024
Same author

Design and Development of a Topical Nanogel Formulation Comprising of a Unani Medicinal Agent for the Management of Pain.

Gels (Basel, Switzerland)·2023
Same author

Current Leads and Marketed Formulations for an Effective Treatment of Fungal Infections.

Infectious disorders drug targets·2023
Same author

Recent Advances in Computer Aided Drug Design.

Current topics in medicinal chemistry·2023
Same author

The Custom R Group Enumeration with Various R Group Libraries at Designated Sites on Amphotericin B.

Current computer-aided drug design·2023

Related Experiment Video

Updated: Jun 2, 2026

Preparation, Characteristics, Toxicity, and Efficacy Evaluation of the Nasal Self-Assembled Nanoemulsion Tumor Vaccine In Vitro and In Vivo
07:33

Preparation, Characteristics, Toxicity, and Efficacy Evaluation of the Nasal Self-Assembled Nanoemulsion Tumor Vaccine In Vitro and In Vivo

Published on: September 28, 2022

Surface engineered nanoparticles for oral immunization.

Basant Malik1, Amit K Goyal, Foziyah Zakir

  • 1ISF College of Pharmacy, Moga 142001, India.

Journal of Biomedical Nanotechnology
|April 14, 2011
PubMed
Summary
This summary is machine-generated.

This study developed RGD peptide-conjugated nanoparticles for oral vaccines. These nanoparticles effectively target M cells in the gut, enhancing both systemic and mucosal immunity for improved oral vaccination strategies.

More Related Videos

Cationic Nanoemulsion-Encapsulated Retinoic Acid as an Adjuvant to Promote OVA-Specific Systemic and Mucosal Responses
06:02

Cationic Nanoemulsion-Encapsulated Retinoic Acid as an Adjuvant to Promote OVA-Specific Systemic and Mucosal Responses

Published on: February 23, 2024

A "Plug-And-Display" Nanoparticle Vaccine Platform Based on Outer Membrane Vesicles Displaying SARS-CoV-2 Receptor-Binding Domain
08:07

A "Plug-And-Display" Nanoparticle Vaccine Platform Based on Outer Membrane Vesicles Displaying SARS-CoV-2 Receptor-Binding Domain

Published on: July 25, 2022

Related Experiment Videos

Last Updated: Jun 2, 2026

Preparation, Characteristics, Toxicity, and Efficacy Evaluation of the Nasal Self-Assembled Nanoemulsion Tumor Vaccine In Vitro and In Vivo
07:33

Preparation, Characteristics, Toxicity, and Efficacy Evaluation of the Nasal Self-Assembled Nanoemulsion Tumor Vaccine In Vitro and In Vivo

Published on: September 28, 2022

Cationic Nanoemulsion-Encapsulated Retinoic Acid as an Adjuvant to Promote OVA-Specific Systemic and Mucosal Responses
06:02

Cationic Nanoemulsion-Encapsulated Retinoic Acid as an Adjuvant to Promote OVA-Specific Systemic and Mucosal Responses

Published on: February 23, 2024

A "Plug-And-Display" Nanoparticle Vaccine Platform Based on Outer Membrane Vesicles Displaying SARS-CoV-2 Receptor-Binding Domain
08:07

A "Plug-And-Display" Nanoparticle Vaccine Platform Based on Outer Membrane Vesicles Displaying SARS-CoV-2 Receptor-Binding Domain

Published on: July 25, 2022

Area of Science:

  • Immunology
  • Nanotechnology
  • Vaccine Development

Background:

  • Oral vaccines require efficient delivery to intestinal immune cells to elicit robust immune responses.
  • M cells in the gut represent a key target for oral vaccine delivery due to their role in sampling luminal antigens.
  • Developing effective carrier systems is crucial for successful oral vaccine design.

Purpose of the Study:

  • To evaluate RGD peptide-conjugated alginate-coated chitosan nanoparticles as a carrier for oral antigen delivery.
  • To target M cells in the gut-associated lymphoid tissue (GALT) for enhanced immune stimulation.
  • To assess the systemic and mucosal immune responses induced by the novel nanoparticle carrier.

Main Methods:

  • Design and synthesis of alginate-coated chitosan nanoparticles.
  • Conjugation of RGD peptide to the nanoparticle surface for M cell targeting.
  • In vivo studies to evaluate antibody titers and immune responses after oral administration.
  • Analysis of release kinetics and immune cell targeting efficacy.

Main Results:

  • Alginate-coated chitosan nanoparticles demonstrated higher antibody titers compared to plain chitosan nanoparticles.
  • RGD peptide conjugation significantly enhanced the targeting of nanoparticles to the GALT.
  • The developed carrier system induced strong systemic and mucosal immune responses.
  • The nanoparticles exhibited favorable release kinetics for sustained antigen delivery.

Conclusions:

  • RGD peptide-conjugated alginate-coated chitosan nanoparticles are a suitable and effective carrier system for oral antigen delivery.
  • This cost-effective carrier construct shows significant potential for developing next-generation oral vaccines.
  • The strategy successfully mimics natural infection pathways to stimulate mucosal immunity.